The ReNAissanCe of mRNA-based cancer therapy
Abstract
About 25 years ago, mRNA became a tool of interest in anticancer vaccination approaches. However, due to its rapid degradation in situ, direct application of mRNA was confronted with considerable skepticism during its early use. Consequently, mRNA was for a long time mainly used for the ex vivo transfection of dendritic cells, professional antigen-presenting cells known to stimulate immunity. The interest in direct application of mRNA experienced a revival, as researchers became aware of the many advantages mRNA offers. Today, mRNA is considered to be an ideal vehicle for the induction of strong immune responses against cancer. The growing numbers of preclinical trials and as a consequence the increasing clinical application of mRNA as an off-the-shelf anticancer vaccine signifies a renaissance for transcript-based antitumor therapy. In this review, we highlight this renaissance using a timeline providing all milestones in the application of mRNA for anticancer vaccination.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Uridine-containing mRNA stimulates the innate immune response and has an established adjuvant function when used as a vaccine.
“Uridine-containing mRNA stimulates the innate immune response and has an established adjuvant function when used as a vaccine.34,35”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [35]
The citation lists haven’t been fetched yet
References 123 · Cited by 95
- Authors
- Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., & Thielemans, K.
- Affiliations
- Vrije Universiteit Brussel (BE)
- Ghent University (BE)
- Corresponding author
- Thielemans, Kris
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2014-09-29
- Volume
- 14
- Issue
- 2
- Pages
- 235-251
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2139511604
- Cited by
- 95
- References
- 123
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 15 · 2023: 10 · 2022: 6 · 2021: 12 · 2020: 6 · 2019: 3 · 2018: 8 · 2017: 10 · 2016: 8 · 2015: 4 · 2014: 2
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Vaccines (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- mRNA vaccines, cancer immunotherapy, dendritic cell transfection, mRNA degradation, immunostimulation
- MeSH terms
- Antigens, Neoplasm, Clinical Trials as Topic, Dendritic Cells, Humans, Immunotherapy, Neoplasms, RNA, Messenger, Vaccination, Vaccines, DNA, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
